NO304136B1 - FremgangsmÕte for fremstilling av et preparat utformet for forlenget og kontrollert frigivelse av medikamentelle peptidsubstanser - Google Patents
FremgangsmÕte for fremstilling av et preparat utformet for forlenget og kontrollert frigivelse av medikamentelle peptidsubstanser Download PDFInfo
- Publication number
- NO304136B1 NO304136B1 NO922885A NO922885A NO304136B1 NO 304136 B1 NO304136 B1 NO 304136B1 NO 922885 A NO922885 A NO 922885A NO 922885 A NO922885 A NO 922885A NO 304136 B1 NO304136 B1 NO 304136B1
- Authority
- NO
- Norway
- Prior art keywords
- peptide
- water
- stated
- trp
- leu
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 49
- 238000000034 method Methods 0.000 title claims description 35
- 239000000126 substance Substances 0.000 title claims description 11
- 238000013270 controlled release Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000000203 mixture Substances 0.000 title description 5
- 238000013265 extended release Methods 0.000 title description 2
- 239000004005 microsphere Substances 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000000839 emulsion Substances 0.000 claims description 18
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000012736 aqueous medium Substances 0.000 claims description 12
- 229920002988 biodegradable polymer Polymers 0.000 claims description 11
- 239000004621 biodegradable polymer Substances 0.000 claims description 11
- 108700012941 GNRH1 Proteins 0.000 claims description 10
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 8
- 239000012071 phase Substances 0.000 claims description 8
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 5
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 4
- 102100022831 Somatoliberin Human genes 0.000 claims description 4
- 101710142969 Somatoliberin Proteins 0.000 claims description 4
- 102000005157 Somatostatin Human genes 0.000 claims description 4
- 108010056088 Somatostatin Proteins 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 238000002474 experimental method Methods 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 229920001281 polyalkylene Polymers 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 229960000553 somatostatin Drugs 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 239000012907 medicinal substance Substances 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 230000002035 prolonged effect Effects 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 108060001064 Calcitonin Proteins 0.000 claims description 2
- 102400000739 Corticotropin Human genes 0.000 claims description 2
- 101800000414 Corticotropin Proteins 0.000 claims description 2
- 102000009025 Endorphins Human genes 0.000 claims description 2
- 108010049140 Endorphins Proteins 0.000 claims description 2
- 102400000321 Glucagon Human genes 0.000 claims description 2
- 108060003199 Glucagon Proteins 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102400000050 Oxytocin Human genes 0.000 claims description 2
- 101800000989 Oxytocin Proteins 0.000 claims description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 2
- 108010071384 Peptide T Proteins 0.000 claims description 2
- 229930182556 Polyacetal Natural products 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 102000003946 Prolactin Human genes 0.000 claims description 2
- 108010057464 Prolactin Proteins 0.000 claims description 2
- 229920002253 Tannate Polymers 0.000 claims description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 2
- 108010004977 Vasopressins Proteins 0.000 claims description 2
- 102000002852 Vasopressins Human genes 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 2
- 229960004015 calcitonin Drugs 0.000 claims description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 2
- 229960000258 corticotropin Drugs 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 2
- 229960004666 glucagon Drugs 0.000 claims description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 230000001452 natriuretic effect Effects 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- 229960001723 oxytocin Drugs 0.000 claims description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical group C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 2
- 239000002745 poly(ortho ester) Substances 0.000 claims description 2
- 229920000728 polyester Polymers 0.000 claims description 2
- 229920006324 polyoxymethylene Polymers 0.000 claims description 2
- 229940097325 prolactin Drugs 0.000 claims description 2
- 239000002461 renin inhibitor Substances 0.000 claims description 2
- 229940086526 renin-inhibitors Drugs 0.000 claims description 2
- 108010080511 serum sodium transport inhibitor Proteins 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 229960003726 vasopressin Drugs 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims 2
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims 1
- 108010068072 salmon calcitonin Proteins 0.000 claims 1
- 210000001625 seminal vesicle Anatomy 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 201000010653 vesiculitis Diseases 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 16
- 239000002245 particle Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000002434 gonadorelin derivative Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010981 drying operation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 238000004388 gamma ray sterilization Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- -1 pamoate Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940075620 somatostatin analogue Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2257—Prolactin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH2178/91A CH683149A5 (fr) | 1991-07-22 | 1991-07-22 | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO922885D0 NO922885D0 (no) | 1992-07-21 |
| NO922885L NO922885L (no) | 1993-01-25 |
| NO304136B1 true NO304136B1 (no) | 1998-11-02 |
Family
ID=4227716
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO922885A NO304136B1 (no) | 1991-07-22 | 1992-07-21 | FremgangsmÕte for fremstilling av et preparat utformet for forlenget og kontrollert frigivelse av medikamentelle peptidsubstanser |
| NO922886A NO304057B1 (no) | 1991-07-22 | 1992-07-21 | Preparat for vedvarende og styrt frigivelse av medikamentell peptidsubstans, anvendelse av preparatet, og fremgangsmåte for fremstilling av preparatet |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO922886A NO304057B1 (no) | 1991-07-22 | 1992-07-21 | Preparat for vedvarende og styrt frigivelse av medikamentell peptidsubstans, anvendelse av preparatet, og fremgangsmåte for fremstilling av preparatet |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US5445832A (es) |
| JP (2) | JP3600252B2 (es) |
| KR (1) | KR930702018A (es) |
| CN (1) | CN1054543C (es) |
| AT (2) | AT403348B (es) |
| AU (2) | AU652844B2 (es) |
| BE (2) | BE1005697A5 (es) |
| BR (1) | BR9205375A (es) |
| CA (2) | CA2074320C (es) |
| CH (2) | CH683149A5 (es) |
| CZ (1) | CZ287585B6 (es) |
| DE (3) | DE4223284C2 (es) |
| DK (2) | DK176218B1 (es) |
| EE (1) | EE03014B1 (es) |
| ES (2) | ES2037621B1 (es) |
| FI (2) | FI106925B (es) |
| FR (2) | FR2679450B1 (es) |
| GB (2) | GB2257909B (es) |
| GR (2) | GR1001446B (es) |
| HR (1) | HRP920229A2 (es) |
| HU (1) | HU218203B (es) |
| IE (2) | IE69967B1 (es) |
| IL (2) | IL102590A (es) |
| IT (2) | IT1259891B (es) |
| LU (2) | LU88151A1 (es) |
| MX (1) | MX9204268A (es) |
| NL (2) | NL194577C (es) |
| NO (2) | NO304136B1 (es) |
| NZ (1) | NZ243643A (es) |
| PH (1) | PH31564A (es) |
| PL (1) | PL169387B1 (es) |
| PT (2) | PT100713B (es) |
| RU (1) | RU2103994C1 (es) |
| SE (2) | SE512670C2 (es) |
| SI (1) | SI9200152B (es) |
| SK (1) | SK280612B6 (es) |
| TW (1) | TW260610B (es) |
| UA (1) | UA35569C2 (es) |
| WO (1) | WO1993001802A1 (es) |
| ZA (2) | ZA925486B (es) |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| FR2693905B1 (fr) * | 1992-07-27 | 1994-09-02 | Rhone Merieux | Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues. |
| US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| DE4320201A1 (de) * | 1993-06-18 | 1995-01-12 | Asta Medica Ag | Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation |
| US6087324A (en) * | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| DE4342092B4 (de) * | 1993-12-09 | 2007-01-11 | Zentaris Gmbh | Langwirkende Injektionssuspension und Verfahren zur Herstellung |
| CA2224381A1 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| US5931809A (en) | 1995-07-14 | 1999-08-03 | Depotech Corporation | Epidural administration of therapeutic compounds with sustained rate of release |
| DE19545257A1 (de) | 1995-11-24 | 1997-06-19 | Schering Ag | Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln |
| KR0162872B1 (ko) * | 1996-04-01 | 1998-12-01 | 김은영 | 용매추출법을 이용한 생분해성 고분자 미립구의 개선된 제조방법 및 이를 이용한 국소염증 질환 치료용 미립구의 제조방법 |
| US20020111603A1 (en) * | 1996-12-02 | 2002-08-15 | Societe De Conseils De Recherches Et D'application | Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process |
| AU5678398A (en) * | 1997-01-29 | 1998-08-18 | Takeda Chemical Industries Ltd. | Sustained-release microspheres, their production and use |
| AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
| JP2002506876A (ja) * | 1998-03-18 | 2002-03-05 | ユニバーシティ テクノロジー コーポレーション | 非晶質ポリマーを含む持続放出性組成物 |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| SE9801288D0 (sv) * | 1998-04-14 | 1998-04-14 | Astra Ab | Vaccine delivery system and metod of production |
| US6270700B1 (en) | 1998-07-23 | 2001-08-07 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Encapsulation of water soluble peptides |
| US20070009605A1 (en) * | 1998-07-23 | 2007-01-11 | Ignatious Francis X | Encapsulation of water soluble peptides |
| EP1240896A3 (en) * | 1998-07-23 | 2003-03-26 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Encapsulation of water soluble peptides |
| WO2000004916A1 (en) * | 1998-07-23 | 2000-02-03 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Encapsulation of water soluble peptides |
| US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| GB2344519B (en) * | 1998-12-07 | 2004-05-19 | Johnson & Johnson Medical Ltd | Sterile therapeutic compositions |
| IT1304152B1 (it) * | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| US6682724B2 (en) | 1999-02-23 | 2004-01-27 | Arch Chemcials, Inc. | Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles |
| US6204308B1 (en) | 1999-03-01 | 2001-03-20 | Novartis Ag | Organic compounds |
| US6317623B1 (en) * | 1999-03-12 | 2001-11-13 | Medrad, Inc. | Apparatus and method for controlling contrast enhanced imaging procedures |
| EP1161257A2 (en) | 1999-03-17 | 2001-12-12 | Novartis AG | Pharmaceutical compositions comprising tgf-beta |
| EP1044683A1 (en) * | 1999-04-15 | 2000-10-18 | Debio Recherche Pharmaceutique S.A. | One-step dispersion method for the microencapsulation of water soluble substances |
| ES2169980B1 (es) * | 1999-12-17 | 2003-11-01 | Lipotec Sa | Microcapsulas para la liberacion prolongada de farmacos. |
| US6309454B1 (en) | 2000-05-12 | 2001-10-30 | Johnson & Johnson Medical Limited | Freeze-dried composite materials and processes for the production thereof |
| JP2004516262A (ja) | 2000-12-21 | 2004-06-03 | ネクター セラピューティクス | 親水性活性剤を含有するマイクロ粒子の製造のための誘発相転移法 |
| MXPA04002446A (es) * | 2001-09-26 | 2004-07-23 | Baxter Int | Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente. |
| US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
| US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
| KR100885070B1 (ko) * | 2002-05-08 | 2009-02-25 | 재단법인서울대학교산학협력재단 | Ｐｌｇａ에 특이적으로 부착하는 올리고 펩타이드 |
| WO2004060387A1 (en) * | 2002-12-27 | 2004-07-22 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| US7655618B2 (en) * | 2002-12-27 | 2010-02-02 | Diobex, Inc. | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| CN101787073B (zh) | 2003-01-28 | 2013-12-25 | 艾恩伍德医药品股份有限公司 | 治疗胃肠病的方法和组合物 |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| AU2004218369A1 (en) * | 2003-03-05 | 2004-09-16 | Pr Pharmaceuticals | Oxytocin controlled release formulations and methods of using same |
| US6987111B2 (en) * | 2003-08-06 | 2006-01-17 | Alkermes Controlled Therapeutics, Ii | Aripiprazole, olanzapine and haloperidol pamoate salts |
| CA2544678C (en) | 2003-11-05 | 2013-12-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
| AU2005269753B2 (en) * | 2004-07-19 | 2011-08-18 | Biocon Limited | Insulin-oligomer conjugates, formulations and uses thereof |
| PT1781264E (pt) | 2004-08-04 | 2013-10-16 | Evonik Corp | Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma |
| ES2255426B1 (es) * | 2004-10-19 | 2007-08-16 | Gp Pharm, S.A. | Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa). |
| EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| WO2006078903A1 (en) * | 2005-01-21 | 2006-07-27 | Matthews Richard H | Radiosensitizer formulations comprising nitrohistidine derivatives |
| WO2006116565A2 (en) * | 2005-04-25 | 2006-11-02 | Amgen Inc. | Biodegradable peptide sustained release compositions containing porogens |
| SI2444079T1 (sl) | 2005-05-17 | 2017-05-31 | Sarcode Bioscience Inc. | Sestavki in postopki za zdravljenje očesnih motenj |
| MX2007015183A (es) * | 2005-06-14 | 2008-02-19 | Baxter Int | Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco. |
| US20070134341A1 (en) * | 2005-11-15 | 2007-06-14 | Kipp James E | Compositions of lipoxygenase inhibitors |
| KR20130024987A (ko) | 2005-12-22 | 2013-03-08 | 노파르티스 아게 | 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제 |
| WO2007089739A2 (en) | 2006-01-27 | 2007-08-09 | Stryker Corporation | Low pressure delivery system and method for delivering a solid and liquid mixture into a target site for medical treatment |
| KR100722607B1 (ko) * | 2006-05-11 | 2007-05-28 | 주식회사 펩트론 | 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법 |
| US7403325B2 (en) * | 2006-05-19 | 2008-07-22 | Xerox Corporation | Electrophoretic display device |
| US7858663B1 (en) | 2007-10-31 | 2010-12-28 | Pisgah Laboratories, Inc. | Physical and chemical properties of thyroid hormone organic acid addition salts |
| US8211905B1 (en) | 2007-05-22 | 2012-07-03 | Pisgah Laboratories, Inc. | Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties |
| US8039461B1 (en) | 2006-11-10 | 2011-10-18 | Pisgah Laboratories, Inc. | Physical states of a pharmaceutical drug substance |
| US7718649B1 (en) | 2006-11-10 | 2010-05-18 | Pisgah Labs, Inc. | Physical states of a pharmaceutical drug substance |
| US20080293695A1 (en) | 2007-05-22 | 2008-11-27 | David William Bristol | Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance |
| US10183001B1 (en) | 2007-05-22 | 2019-01-22 | Pisgah Laboratories, Inc. | Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features |
| US20080293814A1 (en) * | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
| US8426467B2 (en) * | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
| US8329720B1 (en) | 2007-05-22 | 2012-12-11 | Pisgah Laboratories, Inc. | Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties |
| US8722736B2 (en) * | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
| US9421266B2 (en) | 2007-05-22 | 2016-08-23 | Pisgah Laboratories, Inc. | Safety of pseudoephedrine drug products |
| CA3089569C (en) | 2007-06-04 | 2023-12-05 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| LT2500014T (lt) * | 2007-06-06 | 2019-01-25 | Debiopharm International Sa | Lėto atpalaidavimo mikrodalelių farmacinė kompozicija |
| PT2203181T (pt) | 2007-10-16 | 2018-05-10 | Biocon Ltd | Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico |
| EP2209371B1 (en) | 2007-10-19 | 2017-01-04 | SARcode Bioscience Inc. | Compositions and methods for treatment of diabetic retinopathy |
| US8728528B2 (en) | 2007-12-20 | 2014-05-20 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| US8883863B1 (en) | 2008-04-03 | 2014-11-11 | Pisgah Laboratories, Inc. | Safety of psuedoephedrine drug products |
| US8080562B2 (en) | 2008-04-15 | 2011-12-20 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
| WO2009128932A1 (en) * | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Delivery of lfa-1 antagonists to the gastrointestinal system |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US20100062057A1 (en) * | 2008-09-10 | 2010-03-11 | Pronova BioPharma Norge AS. | Formulation |
| WO2010103402A1 (en) | 2009-03-09 | 2010-09-16 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form and a surfactant, and methods and uses thereof |
| WO2011050175A1 (en) | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| ES2363964B1 (es) | 2009-11-20 | 2012-08-22 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados. |
| ES2363965B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm S.A. | Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados. |
| ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
| EP2517697B1 (en) | 2009-12-23 | 2015-01-07 | Sigma-Tau Industrie Farmaceutiche Riunite SpA | Combination composition useful for treating cardiovascular diseases |
| ES2385240B1 (es) | 2010-07-26 | 2013-09-23 | Gp-Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata. |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| EP2705013B1 (en) | 2011-05-04 | 2016-03-30 | Balance Therapeutics, Inc. | Pentylenetetrazole derivatives |
| WO2013072767A1 (en) | 2011-11-18 | 2013-05-23 | Pronova Biopharma Norge As | Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture |
| WO2013150384A1 (en) | 2012-04-04 | 2013-10-10 | Pronova Biopharma Norge As | Compositions comprising omega-3 fatty acids and vitamin d for psoriasis, and methods and uses thereof |
| EP2833740B1 (en) | 2012-04-04 | 2016-09-14 | Pronova BioPharma Norge AS | Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof |
| DK2851085T3 (da) * | 2012-05-14 | 2019-09-09 | Teijin Ltd | Proteinsammensætning steriliseret ved stråling |
| US9085553B2 (en) | 2012-07-25 | 2015-07-21 | SARcode Bioscience, Inc. | LFA-1 inhibitor and methods of preparation and polymorph thereof |
| JP6499591B2 (ja) | 2013-02-25 | 2019-04-10 | シナジー ファーマシューティカルズ インコーポレイテッド | 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト |
| US11351139B2 (en) | 2013-02-28 | 2022-06-07 | Basf As | Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
| JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
| EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| US20160220630A1 (en) | 2013-10-10 | 2016-08-04 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions |
| US10046058B2 (en) | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
| WO2016173923A1 (en) | 2015-04-28 | 2016-11-03 | Pronova Biopharma Norge As | Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis |
| EP3402804A1 (en) | 2016-01-11 | 2018-11-21 | Synergy Pharmaceuticals Inc. | Formulations and methods for treating ulcerative colitis |
| MX2020003681A (es) | 2017-09-26 | 2020-08-03 | Nanomi B V | Metodo para preparar microparticulas por tecnica de doble emulsion. |
| CA3084728A1 (en) | 2017-12-06 | 2019-06-13 | Basf As | Fatty acid derivatives for treating non-alcoholic steatohepatitis |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2010115A1 (de) * | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Mikrogranulaten |
| JPS523342B2 (es) * | 1972-01-26 | 1977-01-27 | ||
| US3976071A (en) * | 1974-01-07 | 1976-08-24 | Dynatech Corporation | Methods of improving control of release rates and products useful in same |
| US4010125A (en) * | 1975-06-12 | 1977-03-01 | Schally Andrew Victor | [D-Trp6 ]-LH-RH and intermediates therefor |
| US4622244A (en) * | 1979-09-04 | 1986-11-11 | The Washington University | Process for preparation of microcapsules |
| US4384975A (en) * | 1980-06-13 | 1983-05-24 | Sandoz, Inc. | Process for preparation of microspheres |
| US4341767A (en) * | 1980-10-06 | 1982-07-27 | Syntex Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
| US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
| PH19942A (en) * | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| CH661206A5 (fr) * | 1983-09-23 | 1987-07-15 | Debiopharm Sa | Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes. |
| JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| DE3678308D1 (de) * | 1985-02-07 | 1991-05-02 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von mikrokapseln. |
| JP2551756B2 (ja) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| US4666704A (en) * | 1985-05-24 | 1987-05-19 | International Minerals & Chemical Corp. | Controlled release delivery system for macromolecules |
| IL79134A (en) * | 1985-07-29 | 1991-06-10 | American Cyanamid Co | Continuous release peptide implants for parenteral administration |
| US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
| US5000886A (en) * | 1987-05-26 | 1991-03-19 | American Cyanamid Company | Silicone-hardened pharmaceutical microcapsules and process of making the same |
| US4800191A (en) * | 1987-07-17 | 1989-01-24 | Schally Andrew Victor | LHRH antagonists |
| US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US5187150A (en) * | 1987-10-14 | 1993-02-16 | Debiopharm S.A. | Polyester-based composition for the controlled release of polypeptide medicinal substances |
| CH672887A5 (es) * | 1987-10-14 | 1990-01-15 | Debiopharm Sa | |
| JP2670680B2 (ja) * | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
| WO1990013361A1 (en) * | 1989-05-04 | 1990-11-15 | Southern Research Institute | Improved encapsulation process and products therefrom |
| HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| CH679207A5 (es) * | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| CH681425A5 (es) * | 1990-11-14 | 1993-03-31 | Debio Rech Pharma Sa | |
| CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
-
1991
- 1991-07-22 CH CH2178/91A patent/CH683149A5/fr not_active IP Right Cessation
-
1992
- 1992-07-15 WO PCT/CH1992/000146 patent/WO1993001802A1/fr active IP Right Grant
- 1992-07-15 BR BR9205375A patent/BR9205375A/pt not_active Application Discontinuation
- 1992-07-15 SK SK382-93A patent/SK280612B6/sk unknown
- 1992-07-15 RU RU93004902A patent/RU2103994C1/ru not_active IP Right Cessation
- 1992-07-15 CZ CZ1993660A patent/CZ287585B6/cs not_active IP Right Cessation
- 1992-07-15 UA UA93004548A patent/UA35569C2/uk unknown
- 1992-07-15 DE DE4223284A patent/DE4223284C2/de not_active Expired - Lifetime
- 1992-07-15 HU HU9301186A patent/HU218203B/hu not_active IP Right Cessation
- 1992-07-15 CH CH882/93A patent/CH683592A5/fr not_active IP Right Cessation
- 1992-07-15 DE DE9219084U patent/DE9219084U1/de not_active Expired - Lifetime
- 1992-07-15 DE DE4223282A patent/DE4223282A1/de not_active Ceased
- 1992-07-15 PL PL92298504A patent/PL169387B1/pl not_active IP Right Cessation
- 1992-07-16 US US07/915,478 patent/US5445832A/en not_active Expired - Lifetime
- 1992-07-20 HR HR920229A patent/HRP920229A2/xx not_active Application Discontinuation
- 1992-07-20 BE BE9200672A patent/BE1005697A5/fr not_active IP Right Cessation
- 1992-07-20 BE BE9200671A patent/BE1005696A3/fr not_active Expired - Fee Related
- 1992-07-21 GB GB9215479A patent/GB2257909B/en not_active Expired - Lifetime
- 1992-07-21 ES ES9201522A patent/ES2037621B1/es not_active Expired - Fee Related
- 1992-07-21 IL IL102590A patent/IL102590A/xx not_active IP Right Cessation
- 1992-07-21 ZA ZA925486A patent/ZA925486B/xx unknown
- 1992-07-21 IL IL102591A patent/IL102591A/xx not_active IP Right Cessation
- 1992-07-21 NL NL9201310A patent/NL194577C/nl not_active IP Right Cessation
- 1992-07-21 NL NL9201309A patent/NL194576C/nl not_active IP Right Cessation
- 1992-07-21 ES ES09201523A patent/ES2050070B1/es not_active Expired - Fee Related
- 1992-07-21 SI SI9200152A patent/SI9200152B/sl unknown
- 1992-07-21 MX MX9204268A patent/MX9204268A/es not_active IP Right Cessation
- 1992-07-21 DK DK199200938A patent/DK176218B1/da not_active IP Right Cessation
- 1992-07-21 GB GB9215480A patent/GB2257973B/en not_active Expired - Fee Related
- 1992-07-21 AT AT0148992A patent/AT403348B/de not_active IP Right Cessation
- 1992-07-21 SE SE9202213A patent/SE512670C2/sv not_active IP Right Cessation
- 1992-07-21 DK DK199200939A patent/DK176219B1/da not_active IP Right Cessation
- 1992-07-21 TW TW081105749A patent/TW260610B/zh active
- 1992-07-21 GR GR920100322A patent/GR1001446B/el unknown
- 1992-07-21 LU LU88151A patent/LU88151A1/fr unknown
- 1992-07-21 CA CA002074320A patent/CA2074320C/en not_active Expired - Lifetime
- 1992-07-21 FI FI923321A patent/FI106925B/fi not_active IP Right Cessation
- 1992-07-21 SE SE9202212A patent/SE512609C2/sv not_active IP Right Cessation
- 1992-07-21 JP JP19431092A patent/JP3600252B2/ja not_active Expired - Fee Related
- 1992-07-21 FR FR9208991A patent/FR2679450B1/fr not_active Expired - Lifetime
- 1992-07-21 PH PH44682A patent/PH31564A/en unknown
- 1992-07-21 AT AT0148892A patent/AT408609B/de not_active IP Right Cessation
- 1992-07-21 CN CN92109509A patent/CN1054543C/zh not_active Expired - Fee Related
- 1992-07-21 GR GR920100323A patent/GR1002548B/el not_active IP Right Cessation
- 1992-07-21 ZA ZA925485A patent/ZA925485B/xx unknown
- 1992-07-21 AU AU20437/92A patent/AU652844B2/en not_active Expired
- 1992-07-21 CA CA002074322A patent/CA2074322C/en not_active Expired - Fee Related
- 1992-07-21 PT PT100713A patent/PT100713B/pt not_active IP Right Cessation
- 1992-07-21 PT PT100712A patent/PT100712B/pt not_active IP Right Cessation
- 1992-07-21 LU LU88150A patent/LU88150A1/fr unknown
- 1992-07-21 IT ITBS920092A patent/IT1259891B/it active IP Right Grant
- 1992-07-21 AU AU20436/92A patent/AU651711B2/en not_active Ceased
- 1992-07-21 IE IE922366A patent/IE69967B1/en not_active IP Right Cessation
- 1992-07-21 IT ITBS920093A patent/IT1259892B/it active IP Right Grant
- 1992-07-21 JP JP4194313A patent/JP2842736B2/ja not_active Expired - Lifetime
- 1992-07-21 NO NO922885A patent/NO304136B1/no not_active IP Right Cessation
- 1992-07-21 FI FI923320A patent/FI105318B/fi not_active IP Right Cessation
- 1992-07-21 NO NO922886A patent/NO304057B1/no unknown
- 1992-07-21 FR FR929208992A patent/FR2680109B1/fr not_active Expired - Fee Related
- 1992-07-21 IE IE922367A patent/IE71199B1/en not_active IP Right Cessation
- 1992-07-21 NZ NZ243643A patent/NZ243643A/en unknown
-
1993
- 1993-03-22 KR KR1019930700851A patent/KR930702018A/ko not_active IP Right Cessation
-
1994
- 1994-03-16 US US08/210,097 patent/US5637568A/en not_active Expired - Fee Related
- 1994-11-21 EE EE9400282A patent/EE03014B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO304136B1 (no) | FremgangsmÕte for fremstilling av et preparat utformet for forlenget og kontrollert frigivelse av medikamentelle peptidsubstanser | |
| NL195056C (nl) | Werkwijze voor het bereiden van preparaten die zouten van peptiden met op carboxy eindigende polyesters bevatten. | |
| FI96278B (fi) | Menetelmä mikrokapselin valmistamiseksi, josta vapautuu pidennetysti luteinisoivaa hormonia vapauttavaa hormonia | |
| EP0052510B2 (en) | Microencapsulation of water soluble polypeptides | |
| US7048947B2 (en) | Sustained-release preparation | |
| HRP20000471A2 (en) | Sustained-release composition, method of its production and the use thereof | |
| RU2128055C1 (ru) | Фармацевтическая композиция замедленного высвобождения и способ ее получения | |
| FR2762319A1 (fr) | Microcapsules presentant une liberation prolongee et leur procede de preparation | |
| JPH05294826A (ja) | ペプチド含有徐放性マイクロカプセル |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |